To assess treatment persistence and virologic outcomes among adults who switched from oral antiretroviral therapy to injectable cabotegravir plus rilpivirine in routine care.
Approach:
: An observational OPERA cohort analysis, described in an IDWeek 2026 abstract, evaluated adults who switched between January 21, 2021, and December 31, 2025, with follow-up through February 28, 2026.
: Of 7,995 patients who switched, 6,955 (87%) had viral loads below 50 copies/mL at initiation. Among this suppressed group, 6,362 completed initiation, defined as receiving the first two injections no more than 67 days apart.
: Outcomes included treatment persistence, viral suppression, injection timing, confirmed virologic failure and provider-reported discontinuation reasons.
Key Findings:
Among the 6,362 patients who completed initiation, 77% remained in care and on injectable therapy at study end, with or without interruptions. Median treatment duration was 18 months.
During the first uninterrupted treatment course, 94% had a viral load below 50 copies/mL at their last measurement, while 81% remained below that threshold at every measurement.
According to Dr. Ricky Hsu, 95% received injections on time or had only one late injection within 5 days of the recommended window.
Confirmed virologic failure occurred in 1%, defined as two consecutive viral loads of at least 200 copies/mL or one measurement at that threshold followed by discontinuation.
Among 182 surveys of provider-confirmed discontinuations, the leading reported reasons were nonadherence to injection visits (29%), loss to care (23%) and a desire to switch to oral therapy (15%).
Interpretation:
The analysis described persistence and virologic outcomes after switching to injectable therapy. The 94% suppression finding concerned the last measurement during the first uninterrupted treatment course among initially suppressed patients who completed initiation, rather than sustained suppression at every measurement.
Limitations:
The observational analysis did not provide a randomized comparison with continued daily oral therapy.
Discontinuation surveys represented 10% of discontinuations.
The abstract did not include financial disclosures or conflict-of-interest statements.
Conclusion:
Among initially suppressed patients who completed initiation, most remained in care and on injectable therapy at study end. Viral suppression was reported in 94% at the last measurement during the first uninterrupted treatment course, while 81% were suppressed at every measurement during that course.